Trial Profile

A phase III study of prasinezumab in patients with early-stage Parkinson's disease

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prasinezumab (Primary)
Indications Parkinson's disease
Focus Therapeutic Use

Most Recent Events

23 Jun 2025 New trial record
16 Jun 2025 According to Roche media release, the company announced its decision to proceed with Phase III development of prasinezumab in early-stage Parkinson's disease. This decision is based on data from the Phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and Phase II PASADENA studies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com